.

Vascular Biogenics traded at $0.16 this Friday September 30th, decreasing $0.001 or 0.83 percent since the previous trading session. Looking back, over the last four weeks, Vascular Biogenics lost 31.04 percent. Over the last 12 months, its price fell by 92.50 percent. Looking ahead, we forecast Vascular Biogenics to be priced at 0.15 by the end of this quarter and at 0.14 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.16
Daily Change
-0.83%
Yearly
-92.50%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Bluebird Bio 6.33 0.63 11.05% -66.91%
Capricor Therapeutics 6.00 0.07 1.18% 51.13%
Infinity Pharmaceuticals 1.19 0 0% -64.58%
Lumos Pharma Inc. 8.85 -0.15 -1.67% -7.72%
Prothena 60.63 1.16 1.95% -14.29%
Vascular Biogenics 0.16 -0.001 -0.83% -92.50%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%

Vascular Biogenics
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.